CTX 101

Drug Profile

CTX 101

Alternative Names: AlloCSC 01; CTX-101

Latest Information Update: 15 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Coretherapix
  • Developer TiGenix
  • Class Heart failure therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Myocardial infarction
  • Preclinical Ventricular tachycardia

Most Recent Events

  • 13 Mar 2017 Top-line efficacy and adverse events data from the phase I/II CAREMI trial in Myocardial infarction released by TiGenix
  • 21 Feb 2017 Coretherapix completes the phase I/II CAREMI trial for Myocardial infarction in Belgium and Spain (EudraCT2013-001358-81)
  • 17 Jun 2016 Efficacy and adverse events data from the CAREMI phase I/II trial in Myocardial infarction released by TiGenix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top